# Hayward Holdings, Inc.: financial statements, quarterly

HAYW · NYSE · CIK 1834622 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hayw.md) · [Financials](/companies/hayw/financials.md) · [Filings](/companies/hayw/filings.md) · [Insiders](/companies/hayw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hayw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [278 d](/filings/0001834622-26-000008.md) | [213](/filings/0001834622-25-000057.md) | [284](/filings/0001834622-25-000110.md) | [228](/filings/0001834622-25-000142.md) | [327 d](/filings/0001834622-26-000008.md) | [229](/filings/0001834622-26-000033.md) | [300](/filings/0001834622-26-000047.md) | [244](/filings/0001834622-26-000055.md) | [349 d](/filings/0001834622-26-000008.md) | [255](/filings/0001834622-26-000033.md) | [318](/filings/0001834622-26-000047.md) | [260](/filings/0001834622-26-000055.md) |
| Cost of revenue | $m | [189 d](/filings/0001834622-26-000008.md) | [116](/filings/0001834622-26-000008.md) | [151](/filings/0001834622-26-000008.md) | [124](/filings/0001834622-26-000008.md) | [174](/filings/0001834622-26-000008.md) | [124](/filings/0001834622-26-000033.md) | [152](/filings/0001834622-26-000047.md) | [128](/filings/0001834622-26-000055.md) | [180 d](/filings/0001834622-26-000008.md) | [137](/filings/0001834622-26-000033.md) | [163](/filings/0001834622-26-000047.md) | [135](/filings/0001834622-26-000055.md) |
| Gross profit | $m | [89.6 d](/filings/0001834622-26-000008.md) | [96.4](/filings/0001834622-26-000008.md) | [133](/filings/0001834622-26-000008.md) | [104](/filings/0001834622-26-000008.md) | [153](/filings/0001834622-26-000008.md) | [105](/filings/0001834622-26-000033.md) | [147](/filings/0001834622-26-000047.md) | [117](/filings/0001834622-26-000055.md) | [169 d](/filings/0001834622-26-000008.md) | [119](/filings/0001834622-26-000033.md) | [155](/filings/0001834622-26-000047.md) | [125](/filings/0001834622-26-000055.md) |
| Research and development | $m | [5.5 d](/filings/0001834622-26-000008.md) | [6.3](/filings/0001834622-25-000057.md) | [6.1](/filings/0001834622-25-000110.md) | [6.4](/filings/0001834622-25-000142.md) | [6.9 d](/filings/0001834622-26-000008.md) | [6.0](/filings/0001834622-26-000033.md) | [6.1](/filings/0001834622-26-000047.md) | [7.1](/filings/0001834622-26-000055.md) | [8.0 d](/filings/0001834622-26-000008.md) | [6.8](/filings/0001834622-26-000033.md) | [7.7](/filings/0001834622-26-000047.md) | [8.6](/filings/0001834622-26-000055.md) |
| Selling, general and administrative | $m | [14.0 d](/filings/0001834622-26-000008.md) | [51.8](/filings/0001834622-26-000008.md) | [51.5](/filings/0001834622-26-000008.md) | [55.3](/filings/0001834622-26-000008.md) | [58.5](/filings/0001834622-26-000008.md) | [57.0](/filings/0001834622-26-000033.md) | [61.5](/filings/0001834622-26-000047.md) | [61.4](/filings/0001834622-26-000055.md) | [67.0 d](/filings/0001834622-26-000008.md) | [62.6](/filings/0001834622-26-000033.md) | [64.3](/filings/0001834622-26-000047.md) | [59.4](/filings/0001834622-26-000055.md) |
| Operating income | $m | [55.5 d](/filings/0001834622-26-000008.md) | [30.9](/filings/0001834622-25-000057.md) | [68.0](/filings/0001834622-25-000110.md) | [33.4](/filings/0001834622-25-000142.md) | [76.5 d](/filings/0001834622-26-000008.md) | [33.5](/filings/0001834622-26-000033.md) | [71.4](/filings/0001834622-26-000047.md) | [41.1](/filings/0001834622-26-000055.md) | [87.3 d](/filings/0001834622-26-000008.md) | [42.5](/filings/0001834622-26-000033.md) | [76.0](/filings/0001834622-26-000047.md) | [50.2](/filings/0001834622-26-000055.md) |
| Income tax | $m | [8.1 d](/filings/0001834622-26-000008.md) | [3.1](/filings/0001834622-25-000057.md) | [9.4](/filings/0001834622-25-000110.md) | [4.4](/filings/0001834622-25-000142.md) | [8.7 d](/filings/0001834622-26-000008.md) | [4.3](/filings/0001834622-26-000033.md) | [14.6](/filings/0001834622-26-000047.md) | [7.2](/filings/0001834622-26-000055.md) | [6.9 d](/filings/0001834622-26-000008.md) | [6.8](/filings/0001834622-26-000033.md) | [13.6](/filings/0001834622-26-000047.md) | [8.7](/filings/0001834622-26-000055.md) |
| Net income | $m | [31.0 d](/filings/0001834622-26-000008.md) | [9.8](/filings/0001834622-25-000142.md) | [37.6](/filings/0001834622-25-000142.md) | [16.5](/filings/0001834622-25-000142.md) | [54.7 d](/filings/0001834622-26-000008.md) | [14.3](/filings/0001834622-26-000055.md) | [44.8](/filings/0001834622-26-000055.md) | [24.0](/filings/0001834622-26-000055.md) | [68.4 d](/filings/0001834622-26-000008.md) | [23.4](/filings/0001834622-26-000055.md) | [45.6](/filings/0001834622-26-000055.md) | [32.4](/filings/0001834622-26-000055.md) |
| Diluted EPS | $ per share | not reported | [0.04](/filings/0001834622-25-000057.md) | [0.17](/filings/0001834622-25-000110.md) | [0.07](/filings/0001834622-25-000142.md) | not reported | [0.06](/filings/0001834622-26-000033.md) | [0.20](/filings/0001834622-26-000047.md) | [0.11](/filings/0001834622-26-000055.md) | not reported | [0.11](/filings/0001834622-26-000033.md) | [0.21](/filings/0001834622-26-000047.md) | [0.15](/filings/0001834622-26-000055.md) |
| Basic EPS | $ per share | not reported | [0.05](/filings/0001834622-25-000057.md) | [0.17](/filings/0001834622-25-000110.md) | [0.08](/filings/0001834622-25-000142.md) | not reported | [0.07](/filings/0001834622-26-000033.md) | [0.21](/filings/0001834622-26-000047.md) | [0.11](/filings/0001834622-26-000055.md) | not reported | [0.11](/filings/0001834622-26-000033.md) | [0.21](/filings/0001834622-26-000047.md) | [0.15](/filings/0001834622-26-000055.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [178](/filings/0001834622-25-000009.md) | [116](/filings/0001834622-24-000038.md) | [215](/filings/0001834622-24-000093.md) | [274](/filings/0001834622-24-000131.md) | [197](/filings/0001834622-26-000008.md) | [181](/filings/0001834622-25-000057.md) | [365](/filings/0001834622-25-000110.md) | [429](/filings/0001834622-25-000142.md) | [330](/filings/0001834622-26-000055.md) | [136](/filings/0001834622-26-000033.md) | [304](/filings/0001834622-26-000047.md) | [236](/filings/0001834622-26-000055.md) |
| Current assets | $m | [725](/filings/0001834622-25-000009.md) | [721](/filings/0001834622-24-000038.md) | [610](/filings/0001834622-24-000093.md) | [650](/filings/0001834622-24-000131.md) | [767](/filings/0001834622-26-000008.md) | [773](/filings/0001834622-25-000057.md) | [831](/filings/0001834622-25-000110.md) | [836](/filings/0001834622-25-000142.md) | [951](/filings/0001834622-26-000055.md) | [948](/filings/0001834622-26-000033.md) | [933](/filings/0001834622-26-000047.md) | [908](/filings/0001834622-26-000055.md) |
| Total assets | $m | [2,946](/filings/0001834622-25-000009.md) | [2,928](/filings/0001834622-24-000038.md) | [2,863](/filings/0001834622-24-000093.md) | [2,890](/filings/0001834622-24-000131.md) | [2,991](/filings/0001834622-26-000008.md) | [2,985](/filings/0001834622-25-000057.md) | [3,037](/filings/0001834622-25-000110.md) | [3,036](/filings/0001834622-25-000142.md) | [3,151](/filings/0001834622-26-000055.md) | [3,136](/filings/0001834622-26-000033.md) | [3,118](/filings/0001834622-26-000047.md) | [3,097](/filings/0001834622-26-000055.md) |
| Current liabilities | $m | [240](/filings/0001834622-25-000009.md) | [214](/filings/0001834622-24-000038.md) | [235](/filings/0001834622-24-000093.md) | [248](/filings/0001834622-24-000131.md) | [313](/filings/0001834622-26-000008.md) | [294](/filings/0001834622-25-000057.md) | [293](/filings/0001834622-25-000110.md) | [262](/filings/0001834622-25-000142.md) | [323](/filings/0001834622-26-000055.md) | [291](/filings/0001834622-26-000033.md) | [280](/filings/0001834622-26-000047.md) | [273](/filings/0001834622-26-000055.md) |
| Total liabilities | $m | [1,635](/filings/0001834622-25-000009.md) | [1,607](/filings/0001834622-24-000038.md) | [1,505](/filings/0001834622-24-000093.md) | [1,517](/filings/0001834622-24-000131.md) | [1,567](/filings/0001834622-26-000008.md) | [1,545](/filings/0001834622-25-000057.md) | [1,539](/filings/0001834622-25-000110.md) | [1,513](/filings/0001834622-25-000142.md) | [1,558](/filings/0001834622-26-000055.md) | [1,524](/filings/0001834622-26-000033.md) | [1,516](/filings/0001834622-26-000047.md) | [1,508](/filings/0001834622-26-000055.md) |
| Long-term debt | $m | [1,107](/filings/0001834622-24-000010.md) | not reported | not reported | not reported | [971](/filings/0001834622-25-000009.md) | not reported | not reported | not reported | [960](/filings/0001834622-26-000008.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,311](/filings/0001834622-26-000008.md) | [1,320](/filings/0001834622-25-000142.md) | [1,357](/filings/0001834622-25-000142.md) | [1,373](/filings/0001834622-25-000142.md) | [1,424](/filings/0001834622-26-000055.md) | [1,439](/filings/0001834622-26-000055.md) | [1,498](/filings/0001834622-26-000055.md) | [1,523](/filings/0001834622-26-000055.md) | [1,593](/filings/0001834622-26-000055.md) | [1,612](/filings/0001834622-26-000055.md) | [1,602](/filings/0001834622-26-000055.md) | [1,588](/filings/0001834622-26-000055.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(32.4) d](/filings/0001834622-26-000008.md) | [(77.2)](/filings/0001834622-25-000057.md) | [287 d](/filings/0001834622-25-000110.md) | [65.9 d](/filings/0001834622-25-000142.md) | [(63.7) d](/filings/0001834622-26-000008.md) | [(5.9)](/filings/0001834622-26-000033.md) | [194 d](/filings/0001834622-26-000047.md) | [94.6 d](/filings/0001834622-26-000055.md) | [(26.9) d](/filings/0001834622-26-000008.md) | [(151)](/filings/0001834622-26-000033.md) | [322 d](/filings/0001834622-26-000047.md) | [53.9 d](/filings/0001834622-26-000055.md) |
| Capital expenditure | $m | [6.3 d](/filings/0001834622-26-000008.md) | [5.4](/filings/0001834622-25-000057.md) | [4.3 d](/filings/0001834622-25-000110.md) | [6.5 d](/filings/0001834622-25-000142.md) | [6.2 d](/filings/0001834622-26-000008.md) | [5.5](/filings/0001834622-26-000033.md) | [6.9 d](/filings/0001834622-26-000047.md) | [7.4 d](/filings/0001834622-26-000055.md) | [8.9 d](/filings/0001834622-26-000008.md) | [7.1](/filings/0001834622-26-000033.md) | [10.3 d](/filings/0001834622-26-000047.md) | [10.9 d](/filings/0001834622-26-000055.md) |
| Share repurchases | $m | [(0.2) d](/filings/0001834622-26-000008.md) | [0.4](/filings/0001834622-25-000057.md) | [0.0 d](/filings/0001834622-25-000110.md) | [(0.4) d](/filings/0001834622-25-000142.md) | [0.4 d](/filings/0001834622-26-000008.md) | [0.0](/filings/0001834622-26-000033.md) | [0.0 d](/filings/0001834622-26-000047.md) | [0.0 d](/filings/0001834622-26-000055.md) | [5.0 d](/filings/0001834622-26-000008.md) | [5.9](/filings/0001834622-26-000033.md) | [58.5 d](/filings/0001834622-26-000047.md) | [51.0 d](/filings/0001834622-26-000055.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [221](/filings/0001834622-24-000038.md) | [221](/filings/0001834622-24-000093.md) | [221](/filings/0001834622-24-000131.md) | [221](/filings/0001834622-25-000057.md) | [221](/filings/0001834622-25-000110.md) | [221](/filings/0001834622-25-000142.md) | [222](/filings/0001834622-26-000033.md) | [222](/filings/0001834622-26-000047.md) | [222](/filings/0001834622-26-000055.md) | [222](/filings/0001834622-26-000033.md) | [221](/filings/0001834622-26-000047.md) | [217](/filings/0001834622-26-000055.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 208,390,131 at 2026-10-26, from the cover of the [10-Q filed 2026-10-28](/filings/0001834622-26-000055.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 12:56 ET. No prices; not investment advice.